Lumida
/CLVT
⌘K
Clarivate PLC

Clarivate PLC

CLVT
$2.39USD↓-0.42%-0.01 today

MARKET CAP

1.5B

P/E (TTM)

3.2x

FWD P/E

3.1x

DAY RANGE

$2 – $2

52W RANGE

$2
$5

AI Summary

Stalk
StalkMedium

CLVT is in an early Stage 1 consolidation with rising 9/21 EMAs and mean-reversion eligibility, supporting a tactical bullish stance. Neutral OB/OS and absence of active bearish patterns suggest price asymmetry favors upside. Price is holding above the short EMAs within a tight range. Execution should be deferred—stalking for pullbacks into the EMAs or the lower end of the consolidation zone.

  • ↑Earnings yield of 1.87% and book-to-price of 3.16x indicate undervaluation.
  • ↑Guidance calls for 2–3% organic ACV growth and $400M FCF by 2026.
  • ↓Q1 net loss of $40M underscores ongoing unprofitability.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Clarivate Plc (NYSE: CLVT) is a leading global provider of trusted insights and analytics, particularly focused on academia, intellectual property, and life sciences. With a strong emphasis on utilizing advanced technologies such as artificial intelligence (AI), Clarivate aims to streamline and enhance decision-making processes for its clients. The company is currently positioned in a transformative phase, undertaking strategic efforts to strengthen its focus on subscription-based business models and optimize its product offerings, particularly amidst growing competition in data-driven insights.

Bull says

  • ↑Earnings yield of 1.87% and book-to-price of 3.16x indicate undervaluation.
  • ↑Guidance calls for 2–3% organic ACV growth and $400M FCF by 2026.
  • ↑AI adoption by 4,800+ institutions cuts manual work 30–60%.
  • ↑Subscription revenue at 93% with renewal rate of 93% drives stability.
  • ↑Reduced debt by $143M, lowering net leverage to ~2.5x.
  • ↑Adjusted EBITDA margin up 200bps to 41% and Q1 FCF $79M.

Bear says

  • ↓Q1 net loss of $40M underscores ongoing unprofitability.
  • ↓Divestitures shave ~$90–100M from revenue, pressuring growth.
  • ↓High short interest reflects investor skepticism and sell pressure.
  • ↓Negative stock momentum signals continued downward trend ahead.
  • ↓Academic funding cuts risk subscription renewals and ACV stability.
  • ↓Severe balance sheet quality concerns cast viability doubts.

Investment themes with CLVT

Buybacks↑ +0.48%

Companies repurchasing their own shares

C · JCI · WFC

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-01-2026neutral

Transcript signals

Bull points

  • This is our fifth consecutive quarter of improved performance. We are off to a solid start to the year, and I am pleased to report that our first quarter financial results have us on pace to achieve our full-year guidance.
  • Revenues were $586 million, supported by continued VCP progress and execution across the portfolio.
  • Organic ACV growth was 1.6%, with subscription organic revenue growth of 1.7%, reflecting increased adoption of subscription-based solution across Clarivate.

Bear points

  • In February, we announced that we are actively pursuing the sales of the life science and healthcare business as part of a broader portfolio rationalization effort.
  • First quarter net loss was $40 million. The $64 million improvement over the prior year was driven by a foreign exchange benefit as well as lower restructuring, income tax, and interest expenses.
  • we expect revenue to decline by about $100 million at the midpoint of the range to $2.36 billion, and that our organic recurring revenue mix, which excludes the impact of the disposals, will improve to between 88% and 90%.
Read full transcript analysis ›